Exagen names John Aballi CEO, succeeding Ron Rocca who resigned

EXAGEN INC.

John Aballi appointed CEO/President and board member effective Oct 16, 2022, replacing Ron Rocca after 11 years.
Aballi previously SVP/GM Urology and CLIA COO at Veracyte; grew urology unit to $120M+ revenue annually.
Aballi receives base salary $525,000, target bonus 50% of base, equity award of 350,000 shares/units vesting 4 years.
Ron Rocca severance: lump sum $424,875, pro-rated incentive compensation, and 9 months COBRA reimbursement.
Rocca's resignation not due to any disagreement with company's operations, policies, or practices.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Fortunato Ron Rocca

President and Chief Executive Officer

XGN · EXAGEN INC.

Effective: 2022-10-16
Successor: John Aballi
Filed: October 20, 2022, 7:59 PM ET

Fortunato Ron Rocca who resigned as President and Chief Executive Officer of the Company and as a member of the Board of Directors, effective as of October 16, 2022.

Appointed

John Aballi

President and Chief Executive Officer

XGN · EXAGEN INC.

Effective: 2022-10-16
Filed: October 20, 2022, 7:59 PM ET

John Aballi has been appointed as President and Chief Executive Officer of the Company and as a member of the board of directors of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fortunato Ron Rocca resigned as President and Chief Executive Officer at EXAGEN INC..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

Fortunato Ron Rocca who resigned as President and Chief Executive Officer of the Company and as a member of the Board of Directors, effective as of October 16, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Aballi was appointed as President and Chief Executive Officer at EXAGEN INC..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

John Aballi has been appointed as President and Chief Executive Officer of the Company and as a member of the board of directors of the Company

View on SEC.gov

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-22-000067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.